1. FDA. Therapeutic Biological Products. Retrieved February 28, 2009, from http://www.fda.gov/cder/biologics/ .
2. Pai, M. P., Mercier, R. C., and Raebel, M. A., Viral hepatitis (Chapter 40 737–760). In: DioPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Well, B. G., and Posey, L. M. (Eds.), Pharmacotherapy—A Pathophysiologic Approach, 6th edition. McGraw-Hill, New York, 2005.
3. Petros, W. P., and Ericson, S., Hematopoiesis (Chapter 98 1793–1804). In: DioPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Well, B. G., and Posey, L. M. (Eds.), Pharmacotherapy—A Pathophysiologic Approach, 6th edition. McGraw-Hill, New York, 2005.
4. Center for Biologics Evaluation and Research. The Classification of Biological Products. Retrieved February 28, 2009, from http://www.fda.gov/cber/ .
5. Buchholz, S., Gangi, V. J., Johnson, A., Little, J., Mendivil, S., Trott, C., Webber, K., and Weinstein, M., Results of a survey of biological drug and device industries inspected by FDA under the Team Biologics Program. PDA J. Pharm. Sci. Technol. 61:211–222, 2007.